- Home
- DGX
as 08-26-2025 4:00pm EST
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
| Founded: | 1967 | Country: | United States |
| Employees: | N/A | City: | SECAUCUS |
| Market Cap: | 20.1B | IPO Year: | 1996 |
| Target Price: | $185.40 | AVG Volume (30 days): | 842.9K |
| Analyst Decision: | Buy | Number of Analysts: | 15 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 8.35 | EPS Growth: | 12.66 |
| 52 Week Low/High: | $146.17 - $185.62 | Next Earning Date: | 10-21-2025 |
| Revenue: | $10,522,000,000 | Revenue Growth: | 12.58% |
| Revenue Growth (this year): | 11.12% | Revenue Growth (next year): | 3.41% |
Stock Insider Trading Activity of Quest Diagnostics Incorporated (DGX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Plewman Patrick | DGX | SVP for Diagnostic Services | Aug 21 '25 | Sell | $185.00 | 1,975 | $365,375.00 | 15,269 | |
| Plewman Patrick | DGX | SVP for Diagnostic Services | Aug 19 '25 | Sell | $183.00 | 4,532 | $829,356.00 | 15,269 | |
| Plewman Patrick | DGX | SVP for Diagnostic Services | Aug 15 '25 | Sell | $180.00 | 1,975 | $355,500.00 | 15,269 |
Latest Quest Diagnostics Incorporated News
DGX Breaking Stock News: Dive into DGX Ticker-Specific Updates for Smart Investing
The Fly
2 days ago
Figma initiated, Okta upgraded: Wall Street's top analyst calls
MT Newswires
2 days ago
Quest Diagnostics Says Haystack MRD Test Granted US FDA Breakthrough Device Designation
PR Newswire
2 days ago
FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics
MT Newswires
2 days ago
Baird Downgrades Quest Diagnostics to Neutral From Outperform, Price Target is $194
Simply Wall St.
5 days ago
Is Quest Diagnostics Set for Growth After Strong 21% Rally in 2025?
MT Newswires
6 days ago
Quest Diagnostics Insider Sold Shares Worth $829,356, According to a Recent SEC Filing
Zacks
6 days ago
Why Is Quest Diagnostics (DGX) Up 8.2% Since Last Earnings Report?
Zacks
6 days ago
Should Quest Diagnostics Stock Be in Your Portfolio Right Now?
Compare DGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DGX Quest Diagnostics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.